Why Mounjaro Has Increased in Price — and What That Means for You

The biggest misconception: providers raised prices to increase their margins

The assumption many people arrive with is that pharmacies or online clinics chose to charge more. It is worth setting that one down gently, because it is not what happened. Eli Lilly, the manufacturer of Mounjaro, revised the UK list price it charges the supply chain, with effect from 1 September 2025. Private pharmacies buy at that list price; their retail prices moved in response. The cause was upstream, not a commercial decision taken by the services patients use.

If you have been asking why Mounjaro has gone up in price, the company has not published a detailed breakdown, but the pattern is consistent with the global trajectory of GLP-1 medicines: high development and manufacturing costs for biologics, growing demand that outpaces production capacity, and the absence of NHS price controls on private prescriptions. What is clear is that the change was significant (as widely reported in August 2025, the highest-dose pen's list price approximately tripled) and that it reshaped the private market overnight.

You can read more about the mechanics of this specific change on our Mounjaro price increase overview, or explore the broader context of tirzepatide pricing in the UK if you want the longer picture before making any decisions.

What private Mounjaro prices actually include, and what they sometimes do not

Since the September 2025 rise, typical private market prices for Mounjaro have ranged roughly £149 to £375 per month depending on dose and provider. Those figures are real, but comparing them directly is harder than it looks. A headline number sometimes covers the medicine alone. The clinical consultation, written prescription, delivery, aftercare access and dose-review support may come as separate charges, or not come at all.

For a prescription medicine taken weekly, aftercare is not a luxury extra. Questions arise mid-treatment: a side effect that needs a prescriber's eye, a dose-increase decision, a week when you are travelling and storage becomes complicated. The cost of handling those moments is either baked into the price or it is not. The full breakdown of what Mounjaro pricing covers is worth reading before any comparison.

Dose also drives cost in a way that is easy to underestimate at the start. Treatment begins at 2.5mg (the starter pen exists to let your body settle, not to do the main clinical work) and typically titrates upward. The 5mg price increase step, for instance, is a moment many patients do not see coming; our page on the 5mg price increase covers what to expect. Monthly spend at the higher maintenance doses is meaningfully different from the 2.5mg starting point.

Where nume sits, and why we are not trying to be the cheapest

At nume, we made a deliberate choice: one transparent price that includes the consultation, the prescription, the medicine, next-working-day tracked delivery and seven-day aftercare. We do not run discount codes, promotional pricing or subscription schemes. We do not split the bill into components and present only the lowest one as the headline.

That means we do not win a race to the bottom on price, and we did not enter one. What we offer instead is a service you can verify. Our pharmacy is registered with the GPhC (registration 9012878, verifiable on their register), and every consultation is read by a named clinician on our clinical team, not by an algorithm. Every repeat order gets the same review before anything is dispatched.

We understand the price rise stings. If you want to understand why the Mounjaro price increase happened and whether treatment is still affordable, the honest answer is: it depends on the dose and on what the price actually buys you. Our treatment page shows current pricing clearly. Start your free consultation and the cost question becomes a real one with a real number, not an estimate.

Why cheapest is the wrong measure for a prescription medicine

Mounjaro is a Prescription-Only Medicine. The MHRA has warned publicly (and seized approximately 20 million doses of illegally traded weight-loss medicines worth around £45 million) that counterfeit pens are circulating online, some containing insulin rather than tirzepatide. The risk is not theoretical.

A seller offering tirzepatide at a price dramatically below the current market, without a clinical assessment, is a red flag regardless of how professional the website looks. The MHRA's Yellow Card scheme allows anyone to report a suspect seller, and the GPhC register lets you verify any online pharmacy before you hand over personal or payment details. Those two steps take about two minutes and tell you almost everything you need to know.

For a medicine that a prescriber has to authorise, that requires storage in a fridge, that interacts with other medicines, and that is titrated based on how your body responds, the question is not who charges the least. The question is whether the clinical oversight, the genuine supply chain, and the ongoing support are actually there. If you want to think through whether treatment is right for your situation, our weight loss treatment overview is a reasonable place to start, and our FAQs cover the questions we hear most often.